Author: Isabelle Van Seuningen
April 22nd 2021 – Audrey VINCENT
A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: first insight of the underlying mechanisms
Dr Audrey VINCENT
Member of Canther Laboratory, Inserm, CNRS, University of Lille, CHU Lille
Thursday April 22nd 2021
11am / 12am
Visioconférence zoom :
https://univ-lille-fr.zoom.us/j/97519033905?pwd=NC9vMUZYbTRMekJmeDhLZUFkZVlsZz09
Meeting ID: 975 1903 3905
Passcode: 513047
April 15th 2021 – Delphine GRYNBERG
The role of cognitive, functional, psychiatric and social impairments in patients with cancer on caregiver’s quality of life: a focus on patients with glioma
Dr Delphine GRYNBERG
Member of SCALab Laboratory, University of Lille
Thursday April 15th 2021
11am / 12am
Visioconférence zoom :
https://univ-lille-fr.zoom.us/j/97519033905?pwd=NC9vMUZYbTRMekJmeDhLZUFkZVlsZz09
Meeting ID: 975 1903 3905
Passcode: 513047
April 8th 2021 – Emmanuelle LETEURTRE
Actualités de la tumorothèque – Alliance Cancer
Pr Emmanuelle LETEURTRE
Member of CANTHER Laboratory, Mucins team, University of Lille and Director of Pathology Institute, CHU Lille
Thursday April 8th 2021
11am / 12am
Visioconférence zoom :
https://univ-lille-fr.zoom.us/j/97519033905?pwd=NC9vMUZYbTRMekJmeDhLZUFkZVlsZz09
Meeting ID: 975 1903 3905
Passcode: 513047
April 1st 2021 – Alessandro FURLAN
New tracks and new tools to overcome treatment resistance in brain tumors
Dr Alessandro FURLAN
Member of CANTHER Laboratory, Plastcity team, University of Lille
Thursday April 1st 2021
11am / 12am
Visioconférence zoom :
https://univ-lille-fr.zoom.us/j/97519033905?pwd=NC9vMUZYbTRMekJmeDhLZUFkZVlsZz09
Meeting ID: 975 1903 3905
Passcode: 513047
Télécharger l’affiche PDF
2021 PhD Day Lauréats – Awardees
D1 : Julie Auwercx
D2 : Clara Lewuillon
D3 : Sarah Trouvilliez
D4 : Erwan Goy
Thursday March 18th 2021 – Xavier THURU
PyrDLones : small molecules against PD1/PD-L1 axis, a success story using the Integrative Chemistry-Biology Technical Facility (PCBI)
Mr Xavier THURU
Member of Leukemia Team at Canther
Jeudi 18 mars 2021
11h / 12h
Visioconférence zoom :
https://univ-lille-fr.zoom.us/j/97519033905?pwd=NC9vMUZYbTRMekJmeDhLZUFkZVlsZz09
Meeting ID: 975 1903 3905
Passcode: 513047
CANTHER awardee of the Fondation ARC – SIGN’IT 2020 – Signatures en immunothérapie – diagnostiquer, prédire et suivre la réponse au traitement
Dr Suman MITRA of CANTHER team”Factors of persistence of leukemic cells” is awardee of the Fondation ARC call – SIGN’IT 2020 – Signatures en immunothérapie – diagnostiquer,
prédire et suivre la réponse au traitement on the project « Synergy between synthetic CAR T cell and endogenous T cell immunity against tumor cells in B-cell
lymphomas ». This project (600 000 €) in collaboration with Pr Franck MORSCHHAUSER, hematologist at Lille hospital (CHU de Lille), will allow studies on CAR-T biomarkers in lymphoma.
CANTHER’s researchers filed a PATENT (N° EP3766544A1) on anti-PD-1/PD-L1 small molecules
Bruno Quesnel and Xavier Thuru (Team “Factors of persistence of leukemic cells” ) have developed small molecules that block the interaction between PD-L1/PD-1 to allow the restoration of the host’s antitumor immune response against dormant tumor cells and more generally to tumors in which PD-L1 participate in immuno-escape.
Pyrazolone derivatives have been identified as having a strong blocking potential of the different interactions between PD-L1/PD-1. These molecules are aimed to be used to block immuno-escape mechanisms in patients in cancer remission, allowing eradication or at least long-term control of minimal residual disease.
CANTHER awardee of the call flash Fondation ARC Cancer & COVID-19.
Dr Martine Duterque-Coquillaud is awardee of the Fondation ARC flash call on Cancer & COVID-19. She studies the relationship betweenprostate cancer and Covid-19: the role of androgens in the regulation of TMPRSS2 expression, key protease in SARS-CoV-2 virus infection.
Expected results: assist in establishing a possible link between androgens and Covid-19, in vitro and in vivo, while also helping to anticipate the risk and severity for patients with prostate cancer depending on whether they are or not treated with hormone therapy.
Project impact: at a cognitive level, understand one of the possible roles of androgens in viral infection in men. At a clinical level, optimize the management of prostate cancer patients.